July 31, 2007 - Implantable defibrillators can reduce the risk of sudden death in high-risk patients with hypertrophic cardiomyopathy, according to a new study conducted at the Hypertrophic Cardiomyopathy Center at the Minneapolis Heart Institute Foundation and published in the July 25 issue of the Journal of the American Medical Association.

July 31, 2007 - GlaxoSmithKline announced the recommendation of an FDA advisory committee to support Avandia’s (rosiglitazone maleate), an oral anti-diabetic medicine, continued availability to patients in the U.S., information which the FDA will consider its final decision-making process.

July 31, 2007 — eCardio Diagnostics announced it is expanding its facilities with a new state-of-the-art diagnostic laboratory located in Houston, TX, to support the company’s continued growth in the cardiac arrhythmia monitoring and diagnosis market.
The additional facility features leading-edge equipment, technologies and connectivity throughout and will serve as the workplace for eCardio’s diagnostic laboratory technologists, reimbursement specialists and several of their information technology staff members.

For more information: www.ecardio.com

July 30, 2007 – The FDA gave Cook Medical, a developer of IVC filters, clearance for a permanent indication for its newest vena cava filter, Celect, which is designed to offer physicians a tool for minimizing the risk of blood clots and pulmonary embolism in their patients.

July 30, 2007 - Outcome Sciences Inc., a medical software developer, announced that it has added a Continuity of Care Records (CCR) functionality to the its Get With The Guidelines (GWTG) Patient Management Tool (PMT), a data collection and reporting platform for patients with coronary artery disease (CAD), heart failure and stroke, as part of a joint effort with the American Heart Association to

July 27, 2007 - Vascular disease frequently shows no symptoms until it is at such an advanced stage that it is difficult or impossible to treat. Narrowing of the carotid or lower extremity arteries and enlargement of the main artery in the abdomen (abdominal aorta) are some examples of this "silent" disease.

Non-invasive ultrasound testing has been used to quickly and accurately detect these vascular problems, and "screening" events have become popular tools for early diagnosis and to increase public awareness about these problems.

July 27, 2007 – Cardiac Science Corp., a cardiac monitoring and defibrillation products company, received Frost & Sullivan’s award for Global Excellence in ECG Monitoring, which recognizes its leadership and innovative vision in the cardiac monitoring marketplace.

Frost & Sullivan determines the Award recipient based on numerous factors, including the company’s business development, competitive strategy and leadership within the Frost & Sullivan ECG Monitoring Industry Research Group.

July 27, 2007 - Medicomp Inc., a wholly owned subsidiary of United Therapeutics Corporation, recently introduced CardioPAL SAVI, an atrial fibrillation (AF) burden statistical package available on an ambulatory cardiac event monitor designed to assess the severity of a patient’s AF over an extended period.

July 27, 2007 - Medicomp Inc., a wholly owned subsidiary of United Therapeutics Corporation, recently introduced CardioPAL SAVI, an atrial fibrillation (AF) burden statistical package available on an ambulatory cardiac event monitor designed to assess the severity of a patient’s AF over an extended period.

July 26, 2007 - St. Jude Medical Inc. announced that the FDA has granted clearance for the 7F Proxis Embolic Protection System, a system designed to extract debris that may become dislodged when an intervention, such as delivering a stent, is performed on patients who have previously undergone a heart bypass procedure using a saphenous vein graft (SVG).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now